Precision BioSciences Inc at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (Virtual) Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Robert Finke - Guggenheim - Analyst : So based on the four-plus years of effort into the allo CAR Ts, what are the key learnings to date and where do we go from here?

Question: Robert Finke - Guggenheim - Analyst : So as we kind of shift into in vivo, let's start on the delivery side. So considering the pros and cons of AAVs and LNPs for delivery, what is your strategy and how do you think about investment into that space? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. APRIL 03, 2023 / 7:20PM, DTIL.OQ - Precision BioSciences Inc at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (Virtual)

Question: Robert Finke - Guggenheim - Analyst : Thank you. Precision has access to gene-editing technology that can be broadly applied across therapeutic development. Could you share the thought process of the current internal pipeline strategy versus the strategic partnership projects?

Question: Robert Finke - Guggenheim - Analyst : Now we touched on a lot there as far as the differentiating technologies. Maybe we could double-click on DMD for sickle cell and maybe both. And just expand on what differentiates ARCUS's size, ability to edit in a specific way. Why do we think that these diseases are well informed for the ARCUS's edits?

Question: Robert Finke - Guggenheim - Analyst : Wonderful. So we've gone a little bit in depth on sickle cell and DMD. Let's touch on HBV for a moment. Preclinical studies have demonstrated reduced S-antigen and DNA. So do you think this would be a stand-alone treatment? Or would you think about combining this with immunomodulator or antiviral activity?

Question: Robert Finke - Guggenheim - Analyst : Excellent. And let's switch to OTC, which should be the first nucleus to advance to CTA.

Question: Robert Finke - Guggenheim - Analyst : Now that leads greatly into the next question, which is what could a 28% gene insertion mean for these patients? Would that be a functionally curative therapy? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. APRIL 03, 2023 / 7:20PM, DTIL.OQ - Precision BioSciences Inc at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (Virtual)

Question: Robert Finke - Guggenheim - Analyst : Excellent. As we move to that point, discussions with regulators are obviously ramping up. And we've seen some back and forth depending on the type of genomic editing programs placed in front of the regulators. So what is your strategy as far as the regulators go and how you think about staggering once into the clinic?

Question: Robert Finke - Guggenheim - Analyst :

Question: Robert Finke - Guggenheim - Analyst : Well, gentlemen, this have been wonderful as you could hear the applause next towards.

Question: Robert Finke - Guggenheim - Analyst : We're quickly running out of time. So, Michael, maybe in our final moments, can you walk us through the key 2023 catalysts of Precision? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. APRIL 03, 2023 / 7:20PM, DTIL.OQ - Precision BioSciences Inc at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (Virtual)

Question: Robert Finke - Guggenheim - Analyst : Thank you very much.